HUTCHMED announced positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib) significantly improves progression-free survival (PFS) and overall survival (OS) in treatment-naïve patients with EGFR-mutated, MET-overexpressing non-small cell lung cancer (NSCLC). The combination reduced disease progression or death risk by 44% in the overall population and 55% in high MET overexpression patients, extending median PFS to nearly 25 months versus about 14 months with TAGRISSO alone. OS was also improved, with median survival extended by nearly 10 months. The all-oral, biomarker-driven treatment offers a potential new standard of care for this patient group. HUTCHMED plans to seek regulatory approval in China for first-line use based on these results.
HUTCHMED's positive Phase III SANOVO trial results come as 76 of 150 priced Health-sector US stocks on Pluang rose today. For readers following health stocks, here is Pluang's market snapshot as of Oct 26, 2026 14:11 WIB: Inovio Pharmaceuticals Inc (INO) gained 6.00% to USD 0.95 with a typical hold time of 43 days, Smith & Nephew plc (SNN) rose 5.47% to USD 30.83 with a typical hold time of 122 days, while Nuvation Bio Inc. Class A (NUVB) declined 5.77% to USD 4.57 with a typical hold time of 10 days.
Bitget has upgraded its Stock Dual Investment product to include tokenized U.S. equities through a partnership with VETA Finance. This allows users to earn fixed-term yields on assets like tokenized NVIDIA, Alphabet, and AMD stocks by choosing buy or...
FTI Consulting appointed Björn Storim as Senior Advisor in Germany to enhance its banking and capital markets advisory services. Storim brings 35 years of global financial experience, including leadership roles at BNY and Credit Suisse. His expertise...
Nvidia announced that its next-generation Vera Rubin chips will generate $40 billion in revenue per gigawatt, a significant increase from the $25 billion generated by the previous Grace Blackwell chips. This improvement highlights Nvidia's strong gro...
Microbiotica presented positive Phase 1b trial results for MB097, a precision microbiome therapy combined with KEYTRUDA, in advanced melanoma patients resistant to anti-PD-1 therapy. The trial showed MB097 was safe, well tolerated, and led to signifi...
STMicroelectronics has introduced the first combination sensors for automotive safety aimed at mass-market vehicles, integrating multi-axis accelerometers and gyroscopes in one package. These sensors support advanced safety features like crash protec...
